Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30916184 | 1.00 | MAPK1 (0.58) | MAPK1MAPTADORA1KDM4EGRAMD1A | |
| SCHEMBL6436553 | 0.90 | MAPK1 (0.49) | MAPK1MAPTADORA1KDM4EGRAMD1A | |
| SCHEMBL25389751 | 0.89 | ESR2 (0.46) | MAPK1MAPTADORA1KDM4EGRAMD1A | |
| SCHEMBL30740130 | 0.87 | MAPK1 (0.45) | MAPK1MAPTADORA1KDM4EGRAMD1A | |
| SCHEMBL30513269 | 0.86 | MAPK1 (0.63) | MAPK1MAPTKDM4EGRM5 | |
| SCHEMBL741667 | 0.82 | MAPK1 (0.59) | MAPK1MAPTKDM4EGRM5 | |
| SCHEMBL30513280 | 0.79 | MAPK1 (0.55) | MAPK1MAPTKDM4EGRM5 | |
| SCHEMBL28474185 | 0.78 | MAPK1 (0.68) | MAPK1GRM5 | |
| SCHEMBL30988529 | 0.78 | MAPK1 (0.45) | MAPK1MAPTGRM5 | |
| SCHEMBL4052245 | 0.77 | MAPK1 (0.67) | MAPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011617-A1 | FUSED HETEROAROMATIC RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州圣域生物医药科技有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119306741-A | Fused-ring heteroaromatic ring compound, intermediate, preparation method and application | 杭州圣域生物医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118946555-A | Compounds having T-structures formed by at least four rings for use in the treatment of cancer and other indications | 瑟拉斯有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-12139498-B1 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240368188-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-11-07 | — | — | US | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111793077-B | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 东莞市东阳光新药研发有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-110267953-B | Tetrahydroimidazo [4,5-C ] pyridine derivatives as inducers of PD-L1 internalization | 因赛特公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-109890819-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | MAPK1 1349/4885MAPT 4475/4885ADORA1 1447/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | MAPK1 2214/4885MAPT 4451/4885ADORA1 1535/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MAPK1 1864/4885MAPT 4271/4885ADORA1 1667/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MAPK1 1864/4885MAPT 4271/4885ADORA1 1667/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MAPK1 1864/4885MAPT 4271/4885ADORA1 1667/4885 |
| US-20240368188-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM1 | MAPK1 2562/4885MAPT 408/4885ADORA1 140/4885 |
| US-12139498-B1 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM1 | MAPK1 2723/4885MAPT 365/4885ADORA1 143/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | MAPK1 936/4885MAPT 3461/4885ADORA1 2436/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | MAPK1 987/4885MAPT 4605/4885ADORA1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.